Phase 2 clinical trial infrastructure for combat-veteran PTSD, in partnership with Mayo.

Executive summary

The problem. Combat-veteran PTSD drug development is chronically under-supported. Roughly 13 to 20 percent of Iraq and Afghanistan combat veterans meet criteria for PTSD. Phase 2 clinical trials for combat-veteran PTSD therapies fail more often than the field can afford, largely because sponsors lack (a) a pharmacodynamic biomarker sensitive to the specific combat-precipitated neurochemistry, (b) an interpretation tool that translates biomarker movement into likely responder or non-responder classification, and (c) a clinical trial site with real access to combat veterans, faculty familiarity with combat trauma neurochemistry, and residents fluent enough in the presentation to run trial visits credibly. Mayo Clinic could be that site. We are building the biomarker and the interpretation tool.

The technology. A Neurochemical Cascade Architecture (NCA) for AI language models with biology-grounded conductance gating (34 functional heads across four tiers), pharmacokinetic decay modeling on ten antagonistic neurochemical dimensions, and a hash-verifiable specialist composition layer. Four USPTO provisional applications on file (63/939,190; 63/962,385; 63/988,485; 64/034,536). Non-provisional consolidation in preparation under the title The Architecture of the Digital Mind. Implemented in Scyla, a proprietary biology-native compiler wholly owned by Nexus Concordat, Inc.

Operational state. A live specialist cell (cardiac_gen3) serves inference behind a signed manifest verifiable by SHA-256 against a public registry at nexusneurodata.com/cell-demo.html. A second specialist substrate (psych_gen1) has 51.5 million tokens loaded, vanilla baseline training in progress on a local RTX A5000. The vets PTSD subset of that corpus is the training target for the veterans PTSD cell (vets_ptsd_v1) that will be the Waypoints MVP.

Primary regulatory pathway: CDER COA Qualification of NeXus AI ART. Letter of Intent v11 submitted July 11, 2026, under §507 of the Federal Food, Drug, and Cosmetic Act (21st Century Cures Act §3011). ART is a computationally-derived multimodal clinical outcome assessment integrating three co-equal input Prongs: Clinical Diagnostic (Composite Neurochemical Stress-Resilience Biomarker Panel, CNSR-Panel, of published peripheral-blood biomarkers with documented PTSD effect sizes), Clinicians Diagnostic (CAPS-5 E-subscale), and Patient-Reported Outcome (validated PRO instruments plus patient linguistic input on protocol-defined cadence). The proposed Context of Use is a hierarchically-ordered secondary endpoint in Phase 2 and Phase 3 PTSD pharmacotherapy trials in adult United States veteran and active-duty service member populations. The CNSR-Panel is NOT proposed for separate qualification under the FDA Biomarker Qualification Program; it functions as an established-biomarker input reference to the ART instrument, with per-tier citations drawn from the peer-reviewed Systematic Literature Review at ptsd.nexusneurodata.com/slr. Late-fusion multimodal architecture; each Prong is modeled independently, and the algorithm emits correlational structure between per-Prong outputs rather than a weighted composite of Prong inputs. Architectural precedent: FDA-cleared UpDoc large-language-model SaMD 510(k) K253281 (cleared December 2025). Robert Michalik JD RAC pro bono regulatory advisor. Jason Alba MBA DBA signed off in writing on the late-fusion architectural choice: "isolates the data from the engine."

Peer-reviewed evidence backbone for the CNSR-Panel input Prong. Formal Systematic Literature Review Protocol v1.6 committed July 12, 2026, live at ptsd.nexusneurodata.com/slr. Round 1 (Levels 1–4, PRISMA-ScR scoping methodology) maps 11 biomarker categories from HPA-axis glucocorticoids and noradrenergic markers through peripheral inflammation, chemokines, neurotrophic factors, neurosteroids, neuronal-injury markers (mTBI-comorbid), metabolic, epigenetic and multi-omic, wearable-derivable autonomic, and smartphone-capturable vocal biomarkers. Level 4 maps which detection methods currently have FDA, CE, or CLIA regulatory approval. Round 2 is registered as a Protocol v1.6 amendment: 24-hour urinary norepinephrine in combat-veteran PTSD, full PRISMA 2020 hypothesis-testing systematic review with ROBINS-E risk-of-bias and GRADE evidence-quality rating.

The MVP demoed at Waypoints kickoff (October 5, 2026). Two working artifacts. First: a chemistry-conditioned combat-veteran PTSD simulator with three canonical archetypes (combat PTSD, moral injury, TBI-comorbid PTSD). Each archetype is a software character with a persistent 10-dimensional neurochemical state, and behavior under interview, perturbation, and simulated time is reproducible, replayable, and signed. Second: the CNSR-Panel input-reference calculation stack (running today on Scyla, `.sy` files at cnsr_panel_score.sy and cnsr_panel_gate.sy) that Mayo can point at real trial-run biomarker inputs when the time comes. Together these two artifacts are the front and back of the Phase 2 clinical trial infrastructure we are asking Mayo to co-develop.

Two-phase framing (this is how the ask sequences). Waypoints Phase 2 (October 2026 through December 2026): non-device training and clinical trial preparation infrastructure. Non-diagnostic. Non-therapeutic. Positioned under the FDA Clinical Decision Support guidance revised January 29, 2026 as HCP-facing decision-support software with the Section IV(3) single-clinically-appropriate-output enforcement discretion in view. Downstream (2027): sponsor-run Phase 2 PTSD pharmacotherapy trials with Mayo as trial site, adopting NeXus AI ART as a hierarchically-ordered secondary endpoint measuring the treatment-emergent DSM-5 Criterion E arousal-and-reactivity trajectory. Shailee Desai maintains Design History File discipline per 21 CFR 820.30, IEC 62304, and IEC 82304 through both phases so the audit trail is defensible from day one.

The team. Marjorie McCubbins BSc Biochem and Molecular Biology, MHA candidate, four years clinical healthcare experience, CEO. Major General Elder Granger MD USA (Ret.), former Deputy Director of TRICARE Management Activity, former Commander of Task Force 44th Medical Command in Iraq, joining the NN Board of Directors — the DoD, TRICARE, and combat-veteran clinical credibility for this specific MVP. Robert Michalik JD RAC (Chief Advisory Officer). Aislinn McCubbins (co-inventor of record on U.S. Provisionals 63/962,385 and 64/034,536, COO of Dynamic Hallucination, Inc.). Jason Alba MBA DBA (Board Director and anchor SAFE investor, alternate point of contact on the CDER COA-Q submission). Shailee Desai MS Regulatory Affairs candidate (Northeastern), Manager of Quality Compliance. Every substantive access is NDA-first.

What we would value from Waypoints. Structured introductions to Mayo psychiatry and clinical-trials faculty with active veterans PTSD research or clinical practice. Faculty curation of the three canonical veterans PTSD archetypes. Mayo's regulatory perspective on the non-device Clinical Decision Support positioning under the January 29, 2026 FDA guidance. Above all, a serious conversation about Mayo as a Phase 2 clinical trial site for a combat-veteran PTSD pharmacotherapy trial that adopts NeXus AI ART as a hierarchically-ordered secondary endpoint. Elder Granger opens the DoD and TRICARE veteran-recruitment channel that most academic trial sites cannot access.

Application answers, Page 1 of 4 · PLACEHOLDER DRAFTS

Drafts only. Marjorie will fine-tune in the actual form, route through Jason and Robert, and submit personally.

1 · Job title / role

Marjorie McCubbins, BSc Biochemistry and Molecular Biology, MHA candidate (Grand Canyon University), four years clinical healthcare experience. Founder and CEO of Nexus Concordat, Inc. (parent, IP holder, four patents pending). Founder and CEO of NeXus Neuroinformatics, Inc. (the healthcare operating subsidiary submitting this application). Inventor of record on all four USPTO provisionals.

2 · Leadership team

• Marjorie McCubbins, BSc · Founder and CEO, Nexus Concordat, Inc. and NeXus Neuroinformatics, Inc. Sole inventor on 63/939,190 and 63/988,485; co-inventor with Aislinn on 63/962,385 and 64/034,536. LinkedIn: [Marjorie to insert URL]
• Major General Elder Granger, MD, USA (Retired) · NeXus Neuroinformatics Board of Directors (seat in process, invited by Robert Michalik July 1, 2026). Former Deputy Director and Program Executive Officer, TRICARE Management Activity, Office of the Assistant Secretary of Defense for Health Affairs; oversaw a $22.5 billion Defense Health Program covering 9.2 million service members, families, and retirees. Former Commander, Task Force 44th Medical Command and Command Surgeon for Multinational Corps Iraq, running the largest U.S. multinational battlefield medical system in recent history. Credentials: ACRP-CP, CHC, NACD Directorship Certification. Owner of THE 5Ps, LLC, a Service-Disabled Veteran-Owned Small Business. Chief Medical Advisor at MedSync Corp. LinkedIn: linkedin.com/in/elder-granger-md-mg-usa-retired
• Robert Michalik, JD, RAC · Chief Advisory Officer, Nexus Concordat / NeXus Neuroinformatics. Twenty-plus years in biopharma and medical-device regulatory affairs. Regulatory Affairs Certified (RAC). Juris Doctor, Suffolk University Law School. AI Software-as-a-Medical-Device subject-matter expert. Administrator of the LinkedIn group "Generative AI (AI/ML) for CMC, QA and Regulatory Professionals in Pharmaceutical, Biologic and Med Tech." Publicly endorsed the Nexus Concordat work on LinkedIn January 27, 2026. Advises on pathway selection under the FDA CDSS guidance (current revision January 29, 2026), the CDER COA Qualification submission for NeXus AI ART (LOI v11 submitted July 11, 2026), and the design-controls posture Shailee is building.
• Jason Alba, MBA, DBA · Board Director, anchor SAFE investor, and alternate point of contact on the CDER COA-Q submission. Founder of EvoSynapse AI. Signed the late-fusion multimodal architectural choice for NeXus AI ART in writing (quoted for investor materials: "isolates the data from the engine"). Reviewed the corporate documents including the Delaware Certificate and NN Articles.
• Aislinn McCubbins · Co-inventor of record on U.S. Provisionals 63/962,385 (Neurochemical Language Model) and 64/034,536 (Scyla biologically-native language). COO of Dynamic Hallucination, Inc. (the entertainment sister subsidiary licensed on the NC patent stack). Co-creator of canon architecture and lore systems.
• Shailee Desai · Manager of Quality Compliance, NeXus Neuroinformatics. MS Regulatory Affairs candidate at Northeastern University. Owns the Design History File under 21 CFR 820.30, IEC 62304, IEC 82304. Building the design-control system even for the current non-device MVP so a future SaMD transition is defensible without rework.

3 · Company website

patent.nexusconcordat.com (architectural and IP documentation)
chroniclesofapocalyptica.com (the product platform)

4 · Pitch deck / executive summary

The Executive Summary section at the top of this page is the canonical 1-page summary for export. Export as PDF and upload.

5-10 · Company address

[Marjorie to confirm: physical operating address, or use Delaware C-Corp registered agent address]

Delaware registered agent (Harvard Business Services, on file as registered agent for Nexus Concordat Inc. since incorporation):

11 · Healthcare sector(s)

• ✅ Digital Health (primary · chemistry-conditioned AI infrastructure serving drug development)
• ✅ Clinical Trials (primary · end target is Phase 2 clinical trial infrastructure for combat-veteran PTSD pharmacotherapy, adopting the CDER COA-qualified NeXus AI ART instrument as hierarchically-ordered secondary endpoint)
• ✅ Healthcare Services (residency training infrastructure and clinical trial site preparation)
• ☐ Medical Devices (intentionally avoided at MVP · CDS positioning under FDA Jan 29, 2026 guidance)
• ☐ Diagnostics (not a diagnostic tool)
• ☐ Therapeutics (not a therapeutic; infrastructure for the therapeutic developer)
• ☐ Other

12 · Problems addressed

Roughly 13 to 20 percent of Iraq and Afghanistan combat veterans meet clinical criteria for PTSD. Psychiatry residents at academic medical centers and at VA training sites must become fluent in three overlapping presentations that current infrastructure cannot reliably simulate: combat-precipitated PTSD, moral injury, and TBI-comorbid PTSD. The current infrastructure has four structural limits.

First, cost. Standardized-patient actor programs at major academic medical centers run upward of one hundred thousand dollars annually and scale linearly with cohort size and training hour.

Second, consistency. Two residents interviewing the same actor get different presentations. Faculty cannot evaluate resident judgment against a fixed ground truth. This is especially damaging for veteran-specific presentations, where the diagnostic distinction between combat PTSD, moral injury, and TBI-comorbid PTSD depends on longitudinal signal.

Third, replay. A human actor cannot be reset to a specific neurochemical baseline on demand. A resident cannot meaningfully practice the same veterans PTSD case three times to internalize dose-response patterns, sleep-disruption cascades, or hypervigilance decay. Longitudinal scenarios across multiple sessions are not constructable deterministically.

Fourth, availability of veteran-specific actors. Actor programs sourced through GME budgets typically have a limited bench of actors who can credibly present combat trauma. Programs at institutions without proximity to a VA facility struggle to give trainees adequate exposure.

We address all four by replacing human standardized patients for veterans PTSD training with software characters whose internal state is biochemically grounded (10-dimensional neurochemistry), deterministically replayable, and auditable by signed inference manifest. Mayo's psychiatry faculty curates the three canonical veterans PTSD archetypes. NN's engine runs the simulator on top of that curation. The MVP scope is bounded: veterans PTSD only, three archetypes only, HCP-facing only.

13 · Roles typically using the solution

• Psychiatry residents at academic medical centers with veteran patient populations (PGY-1 through PGY-4)
• Psychiatry residents at VA training sites
• Psychiatry attendings and faculty running structured veterans PTSD training scenarios and evaluating resident performance
• Medical education directors and curriculum coordinators building longitudinal veterans PTSD case sets
• VA mental-health team members and social workers in continuing education

14 · Roles typically purchasing the solution

• Designated Institutional Officials overseeing Graduate Medical Education at academic medical centers with veteran patient populations
• Department of Psychiatry residency program directors at institutions with active VA rotations
• Vice Deans for Medical Education
• Chief Medical Education Officers at academic medical centers
• Hospital training budget owners with discretion over GME and CME spend
• VA training program directors (VA-CME and VA psychiatry residency infrastructure) · access via the Elder Granger, MG (Ret.) DoD and VA network
• Department of Defense medical-education partners (Uniformed Services University, Walter Reed) · same channel

15 · Competitors

No direct competitor offers a chemistry-conditioned veterans PTSD training simulator with signed-manifest reproducibility.

Standardized-patient actor programs at academic medical centers, and external providers like SP Educator Network, are the institutional default. They are infrastructure we augment (not replace) for the veterans PTSD specific slice, because they cannot deliver the four structural properties above at any price point.

Biofourmis (now merged into CopilotIQ, October 2024) and similar wearables-driven care platforms are the mostly-adjacent AI health category. They target remote patient monitoring and digital biomarkers, not training simulation. They are not competitors in this MVP scope.

General-purpose AI chat wrappers (AI Dungeon-class, generic large-language-model wrappers) exist but do not deliver clinical-grade properties: no biochemical substrate, no reproducibility across sessions, no signed-manifest auditability, no patent-defensible architecture, no regulatory advisory infrastructure. A residency program director cannot ship a general-purpose chatbot to trainees for veterans PTSD education and defend the decision.

Medical simulation software (Simwerx, ScenarioMD, and similar) targets procedural training (intubations, surgical steps, physical exams). None target veterans PTSD residency training with persistent neurochemical state.

The differentiation is the substrate (biology-grounded chemistry driving behavior) plus the verifiability (signed inference manifest, public lineage registry), both protected by four pending USPTO provisionals.

Application answers, Page 2 of 4 · PLACEHOLDER DRAFTS

Drafts only. Marjorie will fine-tune in the actual form, route through Jason and Robert, and submit personally.

16 · Describe your innovation. How is it differentiated from competitors and current best practices?

The innovation is a veterans PTSD training simulator powered by a patent-pending neurochemical AI architecture. A simulated veteran is a software character whose ten-dimensional neurochemical state (cortisol, dopamine, serotonin, norepinephrine, oxytocin, GABA, acetylcholine, endorphins, glutamate, melatonin) sits on the character record. Combat exposure, moral injury, and TBI comorbidity each drive characteristic starting-state signatures and characteristic time-course behavior. Behavior under interview, under perturbation (sleep loss from nightmares, missed medication, environmental trigger like a helicopter overhead, medication change from an SSRI to prazosin), and across simulated time (days to weeks) is generated through a trained specialist cell (vets_ptsd_v1) that has learned the relationships between combat-precipitated neurochemistry, pharmacokinetics, and behavior. The behavior is rendered as clinical narrative through a language bridge (Qwen 2.5 14B, the same bridge proven on cardiac_gen3).

Differentiation against current best practices, three categories:

vs. standardized-patient actor programs (the institutional default in psychiatry residency training including veterans PTSD training): actors cost academic medical centers upward of one hundred thousand dollars annually, present inconsistently across sessions, and cannot be reset to a specific neurochemical baseline on demand. Actors capable of credibly presenting combat trauma are rare and geographically distributed. Our simulator costs effectively no marginal dollars per session after deployment, is byte-exactly replayable across resident cohorts, and can be reset deterministically to any canonical state for longitudinal scenario design. Every resident nationally can access identical training against Mayo-curated ground truth.

vs. AI roleplay and LLM-wrapper tools (AI Dungeon-class products and generic large-language-model chatbots): we are not improvising from a general-purpose model. Every emission is bound to a signed inference manifest. Every cell has a hash-chained lineage in a public Merkle DAG registry. Each architectural primitive is registered as a hashable opcode. Inference is byte-exact reproducible. A residency program director cannot ship a general-purpose chatbot to trainees for a life-and-death topic like veteran suicide risk. They can ship a chemistry-conditioned, Mayo-curated, byte-exact reproducible simulator with signed manifests.

vs. medical simulation software (Simwerx, ScenarioMD, and similar): these target procedural training. None target veterans PTSD residency training with persistent biochemical state. The differentiation is the substrate, not the interface.

The architectural moat sits in four pending USPTO applications and a proprietary biology-native compiler (Scyla) owned in full by Nexus Concordat, Inc. A competitor would need to both infringe the pending claims (memory weighting under 63/939,190, neurochemical language model under 63/962,385, AETHER endocrine transformer heads under 63/988,485, and hash-verifiable specialist composition under 64/034,536) and rebuild the compiler to reproduce the function. Non-provisional consolidation is in preparation under the title The Architecture of the Digital Mind.

17 · Stage of maturity

Working prototype for a sibling domain, MVP for veterans PTSD in flight, demo-ready by October 5, 2026.

The architecture is live and serving inference behind signed manifests. The cardiac specialist cell (cardiac_gen3) is queryable at nexusneurodata.com/cell-demo.html with verifiable byte-exact provenance against a public registry. The psychiatric substrate (psych_gen1) has 51.5 million tokens loaded, vanilla baseline training in progress on a local RTX A5000. The veterans PTSD cell (vets_ptsd_v1) is the Waypoints MVP: training run underway on the vets PTSD subset of the psych_gen1 corpus, HCP-facing simulator UI in build, targeting a live demo at the October 5, 2026 Waypoints kickoff.

18 · Proof points

Each item below is independently verifiable at the URL given, or via the public artifact named.

• Live cardiac specialist cell with signed inference manifest emission. Type a clinical phrase, receive an autoregressive output bound to a SHA-256-verifiable manifest. Public rate-limited access. nexusneurodata.com/cell-demo.html
• Vanilla baseline serving alongside the chemistry-conditioned cell for apples-to-apples emission comparison under matched seed, temperature, and top-k parameters. Visible on the cell-demo page as the right-hand column. Demonstrates that the chemistry-conditioning changes distributional output shape, not just prompt engineering.
• Public cell-lineage registry for byte-exact external verification. patent.nexusconcordat.com/registry/cardiac-registry.json
• Architectural plan documenting the cell-as-opcode-tree unification. patent.nexusconcordat.com/jason-plan.html
• Training plan and trajectory document describing how the trained cells become the substrate the simulator runs on. patent.nexusconcordat.com/sister-cell.html
• Four pending USPTO provisional applications: 63/939,190 (substrate-independent memory weighting), 63/962,385 (neurochemical language model, co-inventor Aislinn McCubbins), 63/988,485 (AETHER endocrine transformer heads), 64/034,536 (Scyla biologically-native language, co-inventor Aislinn McCubbins). Non-provisional consolidation in preparation as The Architecture of the Digital Mind.
• Peer-reviewed academic co-authorship in flight. Preliminary draft "Neither Half Is Sufficient: A Co-Constitutive Architecture for Trustworthy Clinical AI Deployment" (McCubbins and Ferguson) dated July 1, 2026, co-authored with John C. Ferguson MD FACS of The Ferguson Clinic Honolulu and EdAI Systems, referencing all four provisionals.
• Robert Michalik JD RAC public endorsement (January 27, 2026 LinkedIn post): "Nexus Concordat's Aether Protocols is a 'breakthrough' AI tech showing a strong, emerging connection between Large Language Models and neuroscience... A stealthy, but emerging innovator in this novel approach toward LLMs is Marjorie McCubbins, founder of Nexus Concordat."
• Advisory infrastructure and Board formation. Robert Michalik (Chief Advisory Officer, pro bono), Jason Alba (Board Director + anchor SAFE), Elder Granger MG (Ret.) MD (Board seat in process, veterans PTSD credibility), Shailee Desai (Manager of Quality Compliance, DHF discipline). Advisory site live at michalik.nexusconcordat.com.
• Regulatory pathway in flight. CDER COA Qualification Letter of Intent for NeXus AI ART submitted July 11, 2026 (LOI v11) under §507 of the Federal Food, Drug, and Cosmetic Act, proposing ART as a hierarchically-ordered secondary endpoint in Phase 2 and Phase 3 PTSD pharmacotherapy trials in adult U.S. veteran and active-duty service member populations. Peer-reviewed evidence backbone: formal SLR Protocol v1.6 (committed July 12, 2026), Round 1 published Levels 1–4 (PRISMA-ScR scoping, 11 biomarker categories mapped), Round 2 registered (24-h urinary NE in combat-vet PTSD, PRISMA 2020 + ROBINS-E + GRADE). Live at ptsd.nexusneurodata.com/slr. DoW TBIPHRP FY26 evaluation in progress (Translational Research Award vs. Health Systems Research Award fit brief drafted, awaiting Robert review). NSF SBIR Phase I resubmission in flight.
• Corpus discipline. Per-source SHA-256 manifests with verbatim query terms, license attribution, retrieval timestamps. Raw and cleaned data separation enforced at directory level. Documented in CORPUS_PURPOSE.md at the corpus root.

Application answers, Page 3 of 4 · PLACEHOLDER DRAFTS

Drafts only. Marjorie will fine-tune in the actual form, route through Jason and Robert, and submit personally.

19 · Most recent milestones achieved

• July 1, 2026. Elder Granger MD MG USA (Ret.) invited to the NeXus Neuroinformatics Board of Directors (introduction by Robert Michalik). This locks in the veterans PTSD credibility triangle: DoD and TRICARE relationships plus lived-experience combat medical command via Elder Granger, regulatory strategy via Robert Michalik JD RAC, chemistry credentials and CEO role via Marjorie McCubbins.
• July 1, 2026. Preliminary academic co-author draft "Neither Half Is Sufficient" (McCubbins and Ferguson) circulated, co-authored with John C. Ferguson MD FACS (Ferguson Clinic Honolulu, EdAI Systems), referencing all four USPTO provisionals. Second peer-reviewed pillar in flight alongside the patent portfolio.
• July 1, 2026. CDS pathway analysis completed under the FDA guidance revised January 29, 2026 (Section IV(3) enforcement discretion for single clinically appropriate output). vets_ptsd_v1 MVP scoped so that all four §520(o)(1)(E) criteria are satisfied by architecture and intended-use language.
• July 12, 2026. Formal Systematic Literature Review Protocol v1.6 committed. Round 1 (Levels 1–4) published under PRISMA-ScR scoping methodology, mapping 11 biomarker categories with per-category L1 status, L2 biology, L3 assay methodology and reference range, and L4 FDA / CE / CLIA regulatory-approval mapping. Round 2 registered (24-h urinary norepinephrine in combat-vet PTSD, full PRISMA 2020 hypothesis-testing SR with ROBINS-E and GRADE). Live at ptsd.nexusneurodata.com/slr. The SLR is the peer-reviewed evidence anchor for the CNSR-Panel input Prong to NeXus AI ART.
• July 11, 2026. CDER COA Qualification Letter of Intent for NeXus AI Arousal-Reactivity Trajectory (ART) submitted (v11) under §507 of the Federal Food, Drug, and Cosmetic Act (21st Century Cures Act §3011). ART framed as a computationally-derived multimodal COA integrating three co-equal Prongs (Clinical Diagnostic via CNSR-Panel, Clinicians Diagnostic via CAPS-5 E-subscale, PRO via validated instruments + patient linguistic input) with late-fusion architecture invoking UpDoc 510(k) K253281 as precedent. Context of Use: hierarchically-ordered secondary endpoint in Phase 2 / Phase 3 PTSD pharmacotherapy trials in adult U.S. veteran and active-duty populations. CNSR-Panel is explicitly NOT proposed for separate qualification under BQP; it functions as an established-biomarker input reference. Five substantive questions raised to CDER at §10 of the LOI, including a proposed Companion Qualification pathway for TBI-comorbid populations.
• June 29, 2026. DH Inc DUNS 145052451 issued same day via D&B Apple channel free expedite. NN Inc DUNS scheduled for Monday July 6 (same day as the NN Delaware Certificate return via HBS).
• June 25, 2026. NN Inc EIN 42-3415697 issued by the IRS. Business address 614 County Highway 325, Hamilton AL 35570.
• June 24, 2026. Design Control system kickoff with Shailee Desai (Manager of Quality Compliance). DHF discipline stood up under 21 CFR 820.30, IEC 62304, IEC 82304 even for the current non-device MVP.
• June 22, 2026. psych_gen1 corpus pulled (PubMed targeted, OpenFDA labels + FAERS, ChEMBL, ClinicalTrials.gov, NIMH RDoC) with full per-source SHA-256 manifests. Tokenized to 51.5 million tokens against a 76,325-row vocabulary. Vanilla baseline in active training on local RTX A5000. Fourth provisional 64/034,536 (hash-verifiable specialist composition) filed.
• June 22, 2026. Invited by Mayo Clinic Berg Innovation Exchange to apply for the September 2026 Waypoints cohort. Personalized application link issued by David Kim.
• June 21, 2026. cardiac specialist cell + Qwen 2.5 14B language bridge shipped as a production service at nexusneurodata.com/cell-demo.html. Three-to-eight-second end-to-end latency per inference, signed manifest emission, byte-exact verification against a public registry. Rate-limited public access proves the vanilla vs. chemistry-conditioned distributional difference visibly.
• May 31, 2026. cardiac_gen3 specialist cell completes end-to-end training through the 34-head Hodgkin-Huxley cascade on 20 million tokens of curated cardiology corpus. Vanilla baseline trained on identical data for apples-to-apples comparison.
• April 30, 2026. Nexus Concordat, Inc. incorporated as Delaware C-Corporation (File 10605960, EIN 39-2932385) via Harvard Business Services, Order INC794365.
• February 6, 2026. Mutual NDA executed with Robert Michalik JD RAC. Robert publicly endorses the work January 27, 2026 on LinkedIn.
• April 29, 2026. Mutual NDA executed with Jason Alba MBA DBA (signature page May 1). $2,500 initial investment committed to cover Delaware filings and patent work.

20 · Next milestones to achieve · path from Waypoints MVP to a Phase 2 clinical trial at Mayo

The 14-week plan below is the operating plan for the Waypoints MVP. Each row is a deliverable, not an aspiration. Every checkpoint emits a signed manifest that Mayo can byte-verify. The plan sequences into the 2027 Phase 2 clinical trial pathway.

• Weeks 1 to 2 · July 1 to 14, 2026. Extract the veterans PTSD subset from the 51.5M-token psych_gen1 corpus already loaded. Bound the MVP: combat PTSD (deployment-precipitated), moral injury, TBI-comorbid PTSD. Three archetypes only.
• Weeks 3 to 6 · July 15 to August 11, 2026. Complete vets_ptsd_v1 cascade training run through the 34-head Hodgkin-Huxley cascade on the veterans PTSD subset. Vanilla baseline trained on identical data for apples-to-apples comparison. Same pattern that shipped cardiac_gen3.
• Week 6 · August 12, 2026. RAPS Boston keynote (already scheduled). Pre-MVP demo of vets_ptsd_v1 shown to a room of AI regulatory professionals. Robert curates the framing.
• Weeks 7 to 8 · August 12 to 25, 2026. HCP-facing simulator UI built. Wraps vets_ptsd_v1 emission through the Qwen 2.5 14B bridge already proven on cardiac. Text-only interface at MVP. Faculty-facing evaluation UI parallel track.
• Weeks 9 to 10 · August 26 to September 8, 2026. Signed manifest emission integrated. vets_ptsd_v1 cell hash-linked in the public lineage registry. Byte-exact verification recipe published alongside the cardiac recipe.
• Weeks 11 to 12 · September 9 to 22, 2026. Waypoints application submitted September 20. Elder Granger and Robert Michalik walk the internal simulator dry-run. Any Mayo-facing polish applied.
• Weeks 13 to 14 · September 23 to October 5, 2026. Buffer window. Load-test, fix any regressions, dogfood with Robert plus one veteran-adjacent clinician.
• October 5, 2026 · Waypoints Phase 2 kickoff. Live vets_ptsd_v1 MVP demonstrated to the Mayo Waypoints cohort. Ready to be pointed at Mayo-curated archetype refinements immediately.
• October to December 2026 · the 12-week Waypoints engagement. Mayo psychiatry faculty curates the three archetypes. Residents interact with the simulator in structured sessions. Faculty evaluate resident judgment against ground truth. Signed inference manifests archive every session.
• Q4 2026. Non-provisional patent conversion (63/939,190 due first, others follow) under the title The Architecture of the Digital Mind.
• Q4 2026 (parallel to Waypoints engagement). CDER COA-Q Qualification Plan drafted following LOI acceptance. Plan development follows the four measurement principles from the CDER COA Qualification Program Standard of Evidence (content validity, reliability, construct validity, ability to detect change). SLR Round 2 executed (24-h urinary NE, PRISMA 2020 + ROBINS-E + GRADE). Under Robert Michalik's regulatory direction with any Mayo regulatory input flagged through the Waypoints engagement.
• Q1 2027. Content-validity qualitative research (concept-elicitation + cognitive-debriefing interviews with adult U.S. veteran and active-duty PTSD patients receiving pharmacotherapy) commences in coordination with an academic clinical site under negotiation. Methodology follows the FDA Patient-Reported Outcome Measures guidance (2009) and the ISPOR Task Force for Translation and Cultural Adaptation. Pre-engagement with a candidate Phase 2 sponsor for a Mayo-hosted PTSD pharmacotherapy trial. Elder Granger's DoD and TRICARE relationships open the veteran-recruitment pipeline.
• Q2 2027. Sponsor-run Phase 2 PTSD pharmacotherapy trial protocol finalized with Mayo Clinic as the primary trial site. Protocol adopts NeXus AI ART as a pre-specified hierarchically-ordered secondary endpoint measuring the treatment-emergent DSM-5 Criterion E arousal-and-reactivity trajectory across the treatment window (trajectory magnitude via trapezoidal-rule AUC of the multidimensional state vector; trajectory volatility via SD of first differences). Primary endpoint remains change in CAPS-5 total severity score (Weathers et al., 2018).
• Q3 2027. Phase 2 trial enrollment opens at Mayo. Elder Granger's SDVOSB status (THE 5Ps, LLC) opens the DoD contracting side for federal-trial funding channels. ART deployed once-daily patient-linguistic-input cadence per LOI v11 §7.
• Q4 2027 through 2028. Trial conduct, interim analyses, publication. Joint Mayo-Nexus co-authorship on the ART validation cohort paper. Publication in a peer-reviewed journal. Full ART Qualification Package assembled for CDER submission on the Mayo cohort as the load-bearing content-validity + construct-validity + responsiveness evidence.
• 2028 downstream. Successful Phase 2 readout supports (a) Phase 3 planning with sponsor, (b) pharma licensee interest in adopting the CDER-qualified NeXus AI ART instrument as a hierarchically-ordered secondary endpoint in their own PTSD pharmacotherapy programs (non-exclusive licensing pattern, precedent MDS-UPDRS in Parkinson's and ALSFRS-R in ALS), and (c) additional Mayo-Nexus trial sites (VA-affiliated academic medical centers). Sixth specialist cell trained by Mayo faculty guidance.

21 · How Mayo Clinic can help

• ✅ Clinical Trials · The core ask. Mayo as a Phase 2 clinical trial site for a combat-veteran PTSD pharmacotherapy trial that adopts NeXus AI ART as a hierarchically-ordered secondary endpoint measuring the treatment-emergent DSM-5 Criterion E arousal-and-reactivity trajectory. Mayo brings the trial-execution infrastructure, IRB, patient recruitment (paired with Elder Granger's DoD and TRICARE channels for veteran outreach), Phase 2 monitoring, and the academic credibility to attract a pharma trial sponsor.
• ✅ Clinical Insights · Mayo psychiatry faculty curate the three canonical veterans PTSD archetypes (combat PTSD, moral injury, TBI-comorbid PTSD) and provide faculty review of the CNSR-Panel input-reference specification per the SLR v1.6 tier stratification. Content-validity qualitative research per FDA Patient-Reported Outcome Measures guidance (2009) is the highest-leverage upstream contribution before any patient is enrolled.
• ✅ Co-development · Joint publication of the ART validation strategy and multimodal COA architecture. Mayo-branded trial site protocol. Methodology aligned with Mayo Clinic clinical-trial standards.
• ✅ Research · The CDER-qualified NeXus AI ART instrument becomes a reusable research substrate for combat-veteran PTSD trial infrastructure across multiple drug candidates. Non-exclusive licensing pattern (precedent MDS-UPDRS in Parkinson's, ALSFRS-R in ALS). Mayo faculty co-authorship on publications.
• ✅ Product Testing · During the Waypoints engagement, Mayo psychiatry residents interact with the vets_ptsd_v1 simulator (Phase 2 trial staff training substrate) while Mayo faculty pressure-test the CNSR-Panel input-reference calculation stack against synthetic and (with IRB approval) selected real veteran biomarker samples. This is the pre-trial dry run.
• ✅ Data · Mayo's expert-validated definitions for the three archetypes, the CNSR-Panel reference distribution for a Mayo veteran patient population, and the trial-protocol scaffolding needed to move from Waypoints into a sponsor-run Phase 2 trial that carries ART as secondary endpoint.
• ☐ Other

22 · Current engagement with Mayo Clinic

No formal engagement currently. The communication channel established to date is:

• David Kim, Business Analyst, Mayo Clinic Berg Innovation Exchange. Initial outreach: March 22, 2026 (inquiry about Waypoints Program submission). Response: June 22, 2026 (formal invitation to apply for the September 2026 cohort with personalized application link).

23 · Mayo Clinic experts for Research

We are not yet certain which specific Mayo Clinic research collaborators we would engage. The characteristics and experience we are looking for, all pointed at the Phase 2 clinical trial end target:

• Mayo Clinic Department of Psychiatry and Psychology faculty with active veterans PTSD research or clinical practice with veteran patient populations
• Faculty with Phase 2 clinical trial principal investigator experience in psychiatric drug development (the operational role in a Mayo-Nexus Phase 2 study)
• Faculty with publication record in computational psychiatry, combat trauma neurochemistry, moral injury as a distinct clinical entity, or biomarker validation for psychiatric conditions
• Faculty with experience in TBI-comorbid PTSD (TBI overlap complicates the diagnostic and biomarker picture; this is directly on the CNSR-Panel path)
• Faculty at Mayo's Center for Individualized Medicine with pharmacogenomic and pharmacokinetic modeling experience relevant to SSRI, SNRI, prazosin, and MDMA-assisted therapy pharmacokinetics on the veterans PTSD path
• Mayo Clinic collaborators in the Mayo Clinic Center for Clinical and Translational Science with veterans-affiliated trial history
• Mayo Clinic Simulation Center or Multidisciplinary Simulation Center staff to run the trial-staff training substrate during Phase 2
• Mayo Clinic collaborators active in the VA or DoD research space; Elder Granger MG (Ret.) convenes the DoD side, Mayo brings the academic-clinical side

Rationale: the end target is a Phase 2 clinical trial. The expert mix above maps onto principal investigator, biomarker validation, protocol design, trial site operations, and the DoD-academic bridge. Cardiac Medicine research collaboration is a separate track that would only start after the combat-veteran PTSD Phase 2 protocol is stable.

Application answers, Page 4 of 4 · PLACEHOLDER DRAFTS

Drafts only. Marjorie will fine-tune in the actual form, route through Jason and Robert, and submit personally.

24 · Do you have funding for your Research study?

No.

Nexus Concordat Inc. has no research-study budget earmarked at this time. The Waypoints engagement is meant in part to help scope what a research project would look like and what its funding requirements would be. Any subsequent research collaboration would require its own funding round, which we expect to be a separate conversation downstream of Waypoints.

25 · Mayo Clinic experts for Product Testing

Product testing spans two layers. Waypoints layer (Oct to Dec 2026): Mayo psychiatry residents interacting with the vets_ptsd_v1 simulator plus Mayo faculty pressure-testing the CNSR-Panel input-reference calculation stack against synthetic and (with IRB approval) selected real veteran biomarker samples. Downstream layer (Q3 2027 onward): Mayo as Phase 2 clinical trial site running the sponsor-run pharmacotherapy protocol with NeXus AI ART as hierarchically-ordered secondary endpoint. Expert mix:

• Mayo psychiatry Phase 2 clinical trial principal investigator (the eventual PI on the veteran PTSD Phase 2 study)
• Mayo psychiatry residency program director or vice chair for education (the trial-staff training substrate owner)
• Mayo Clinic Center for Clinical and Translational Science leadership (IRB pathway, protocol scaffolding, trial infrastructure)
• Mayo faculty running standardized-patient programs in psychiatry with veteran patient exposure (the substrate the vets_ptsd_v1 simulator interoperates with during trial-staff training)
• Mayo Clinic laboratory medicine SMEs with expertise in cortisol, catecholamine, and inflammatory biomarker assay methodology (relevant to the CNSR-Panel constituent measurements)
• Mayo Clinic Berg Innovation Exchange innovation and technology-transfer staff (engagement structure, pathway navigation, IP framework)
• Regulatory affairs SMEs at Mayo familiar with FDA Phase 2 pathways for pharmacotherapy trials that carry a hierarchically-ordered secondary COA endpoint (complementary to Robert Michalik JD RAC)

Rationale: the Phase 2 deliverable is a Mayo-Nexus combat-veteran PTSD drug trial. The expert mix owns each layer of that trial (principal investigator, trial-staff training, translational science, biomarker assay, IP, regulatory).

26 · Do you have funding for Product Testing?

No.

The Waypoints engagement model is benefactor-funded at no cost to participating innovators. The product testing we are proposing (residents training against the simulator) sits inside that engagement window. Beyond Waypoints, a Mayo-deployed pilot would require funding scoping that we expect to address through subsequent conversations with Mayo's innovation staff or jointly identified partners.

27 · Data needs specifications and quantities

Data needs split into two tranches keyed to the two-phase framing above.

Waypoints tranche (Oct to Dec 2026): curated educational content only. No protected health information.

• Three canonical veterans PTSD archetypes. Combat PTSD (deployment-precipitated), moral injury, TBI-comorbid PTSD. For each archetype: Mayo's expert-validated definition of the canonical neurochemical signature, characteristic clinical presentation pattern, expected trajectory under SSRI, SNRI, prazosin, and trauma-focused therapy.
• Approximately 5 to 8 anonymized simulation scenarios drawn from Mayo's standardized-patient training library, veterans PTSD focused.
• Mayo's expert-validated taxonomy for the veterans PTSD differentials (combat PTSD vs. moral injury vs. TBI-comorbid).
• CNSR-Panel reference distribution parameters for a Mayo veteran patient population. Aggregate statistical parameters for the CNSR-Panel constituent biomarkers (cortisol, DHEA, norepinephrine, epinephrine, CRP, IL-6, allopregnanolone, BDNF) in Mayo's veteran patient population. No individual patient data. Distribution parameters only.

Phase 2 clinical trial tranche (Q3 2027 onward, subject to IRB approval and Data Use Agreement):

• De-identified biomarker samples from Mayo veteran patients meeting enrollment criteria, used to validate the CNSR-Panel calculation stack against real-world signal before trial randomization opens.
• Trial-protocol scaffolding aligned with Mayo Clinic clinical-trial standards.
• Adverse-event monitoring workflow integration compatible with Mayo's clinical trial safety infrastructure.

All Phase 2 tranche data flows through a DUA between Nexus Concordat and Mayo Clinic with IRB oversight. Format specifications to be scoped during the Waypoints engagement.

28 · Do you have funding to purchase or license data?

No.

We are not proposing a data purchase or licensing transaction. The data described in question 27 is curated educational content we would seek through the Waypoints co-development structure. If Mayo's policies require a separate licensing or data-use agreement for curated training content, we are open to scoping that.

29 · Other areas of support needed

• ✅ Legal/Regulatory Guidance · For the conversion of pending provisional patents to non-provisional applications, and for Mayo's regulatory perspective on the proposed non-device positioning.
• ☐ New Market Entry
• ☐ Manufacturing/Development
• ✅ Partner · Mayo as the validation partner for the simulated-patient training pilot.
• ☐ Office Space
• ☐ Specialized Space (Lab or Otherwise)
• ☐ Specialized Equipment
• ☐ Investment · Not the Waypoints ask. May be relevant in a separate downstream conversation.
• ✅ Other

30 · If "Other," describe the area(s) of support needed

Academic credibility and publication path. Joint validation publication co-authored with Mayo psychiatry faculty would convert our prototype into infrastructure that other academic medical centers can adopt.

31 · Legal and/or regulatory guidance needed

Nexus Concordat and NeXus Neuroinformatics operate with Robert Michalik JD RAC as Chief Advisory Officer (regulatory) working pro bono, and Shailee Desai MS RA candidate as Manager of Quality Compliance. The areas where institutional engagement with Mayo Clinic would meaningfully extend the regulatory posture, bounded to the veterans PTSD MVP:

1. Non-device Clinical Decision Support positioning validated with Mayo. The vets_ptsd_v1 MVP is architected to satisfy the four criteria of FD&C Act §520(o)(1)(E) under the FDA CDS guidance current revision January 29, 2026 (docket FDA-2017-D-6569, document GUI01400062). The January 29 revision added Section IV(3) enforcement discretion for single clinically appropriate output. Mayo's regulatory perspective on the intended-use scoping, the "independent review" affordances in the HCP UI, and the explicit non-time-critical labeling would strengthen the analytical record. We are not asking Mayo to serve as primary regulatory counsel. Robert continues in that role.
2. Design History File review under 21 CFR 820.30 and IEC 62304, even though the current MVP is non-device. Shailee's DHF discipline is being built so that a future SaMD transition (if data ever supports one) is defensible without rework. Mayo's operational familiarity with the DHF construct at the multidisciplinary simulation center or health-informatics side would be a useful review.
3. IRB posture for the residency training pilot. Training software used with residents (not patients) typically sits outside standard clinical IRB scope. Mayo's IRB or Human Research Protection Program can confirm whether the residency-facing use case is IRB-exempt or requires expedited review at Mayo. This clarifies the operational path for Phase 2.
4. Data Use Agreement for curated educational content. A formal DUA governing Mayo's provision of the three canonical veterans PTSD archetype definitions and the 5 to 8 residency scenario templates. Legal alignment on IP ownership of any Mayo-refined archetypes and on citation-and-attribution mechanics.
5. IP collaboration framework. Nexus Concordat holds four pending USPTO provisionals (63/939,190; 63/962,385; 63/988,485; 64/034,536). Non-provisional consolidation is in preparation as The Architecture of the Digital Mind. Mayo's technology transfer office likely has a standard collaboration agreement we would review, particularly around joint inventions, field-of-use restrictions, and licensing terms for Mayo-improved archetypes.
6. Liability and indemnification during the residency pilot. Clear allocation of liability for training software used with residents, including any required cyber-liability coverage Mayo would expect us to carry during the pilot window.

The current FDA CDSS Section IV(3) enforcement discretion is a material update from the September 2022 version, and Marjorie or Robert is prepared to walk Mayo's regulatory staff through the analysis if that would help.

32 · Do you have funding for legal and regulatory guidance?

No.

Nexus Concordat operates with pro bono regulatory advisory in place (Robert Michalik JD RAC). NeXus Neuroinformatics has Shailee Desai on the Design Control system. Patent prosecution costs (filing fees, conversion to non-provisional under the title The Architecture of the Digital Mind) are funded out of the founder's resources plus Jason Alba's $2,500 initial SAFE tranche. Institutional legal-and-regulatory engagement spend is not budgeted. Any work arising from a Mayo collaboration would be a separate scoping conversation.

33 · Current engagement with Mayo Clinic

No formal engagement currently. The communication channel established to date is:

• David Kim, Business Analyst, Mayo Clinic Berg Innovation Exchange. Initial outreach: March 22, 2026 (inquiry about Waypoints Program submission). Response: June 22, 2026 (formal invitation to apply for the September 2026 cohort with personalized application link).

34 · Most recent funding classification

Bootstrapped.

Nexus Concordat Inc., the patent-holding entity submitting this application, is self-funded. The operating company built on the Nexus Concordat patent portfolio (Dynamic Hallucination, Inc.) has accepted angel investment. The Nexus Concordat IP holding entity itself has not raised institutional capital.

Application answers, Page 4 of 4 (final) · PLACEHOLDER DRAFTS

Drafts only. Marjorie will fine-tune in the actual form, route through Jason and Robert, and submit personally.

35 · Prior incubator / accelerator / innovation program participation

No prior participation in formal incubators, accelerators, or venture studios.

NeXus Neuroinformatics, Inc. has been built independently, with the following external support structure:

• Robert Michalik JD RAC · Chief Advisory Officer. Pro bono. Twenty-plus years biopharma and medical-device regulatory affairs. Currently leading the CDER COA Qualification submission for NeXus AI ART (LOI v11 filed July 11, 2026), the CDS pathway analysis under the January 29, 2026 FDA guidance, and the introduction of Elder Granger.
• Jason Alba MBA DBA · Board Director, anchor SAFE investor, alternate point of contact on the CDER COA-Q submission. Founder of EvoSynapse AI. Signed the late-fusion multimodal architectural choice for NeXus AI ART: "isolates the data from the engine."
• Elder Granger MD MG (Ret.) · NeXus Neuroinformatics Board of Directors invitation in flight (July 1, 2026). Former Deputy Director TRICARE Management Activity, former Commander Task Force 44th Medical Command Iraq. NACD Directorship certified.
• Shailee Desai MS RA candidate · Manager of Quality Compliance. Design Control system and Design History File.
• Other parallel non-dilutive tracks in flight: CDER COA Qualification Letter of Intent for NeXus AI ART (v11 submitted July 11, 2026, under §507 FD&C Act), formal SLR Protocol v1.6 (committed July 12, 2026) at ptsd.nexusneurodata.com/slr as the peer-reviewed evidence anchor for the CNSR-Panel input Prong, NSF SBIR Phase I resubmission, DoW TBIPHRP FY26 evaluation (Translational Research Award vs. Health Systems Research Award fit brief drafted for Robert).

The Mayo Clinic Berg Innovation Exchange Waypoints Program would be our first formal innovation-program participation.

36 · Referral / how did you learn of the Berg Innovation Exchange?

PLACEHOLDER · Marjorie to fill in personally with the accurate factual answer (independent research, network referral, etc.). The initial outreach to David Kim was on March 22, 2026.

37 · Additional supporting documents (up to 5, 10 MB each)

Upload bundle, prioritized to fit the 5-file limit, MVP-focused:

1. Executive summary PDF (veterans PTSD focus) · two pages, generated from the Executive Summary section at the top of this page.
2. Patent portfolio one-pager (PDF) · four pending USPTO provisionals (63/939,190; 63/962,385; 63/988,485; 64/034,536) with filing dates, core claims, and non-provisional consolidation timeline under the title The Architecture of the Digital Mind.
3. Cardiac cell as sibling proof (PDF or short recorded demo) · signed inference manifest example with SHA-256 verification recipe, demonstrating the live cardiac_gen3 product at nexusneurodata.com. Establishes that the vets_ptsd_v1 MVP is not a paper claim.
4. Team credential summary (PDF) · one page each: Marjorie (chemistry + MHA + CEO), Elder Granger (TRICARE Deputy Director + Iraq combat medical command + NACD), Robert Michalik (JD + RAC + 20 years biopharma), plus one paragraph each on Aislinn, Jason, Shailee.
5. Veterans PTSD MVP scope document (PDF) · the 14-week milestone plan from Q20 with checkpoints, deliverables, and the October 5 Waypoints kickoff demo target.

38 · Keywords and terms for classification

Suggested keyword list (use commas in the actual form):

Veterans PTSD, combat-veteran PTSD, moral injury, TBI-comorbid PTSD, psychiatry residency simulation, veterans mental health training, VA psychiatry education, Neurochemical Cascade Architecture, neurochemical language model, Hodgkin-Huxley cascade, pharmacokinetic decay modeling, brain-aligned language models, computational psychiatry, standardized patient training replacement, clinical decision support, non-device medical software, FDA CDS January 2026 guidance, 21st Century Cures Act Section 3060, specialist cell architecture, signed inference manifests, byte-exact lineage, chemistry-conditioned AI, Scyla biology-native compiler, cardiac specialist cell, psych_gen1, vets_ptsd_v1, TRICARE, DoD medical education, SDVOSB partnership, Mayo Clinic Berg Innovation Exchange Waypoints, October 5 Phase 2 kickoff

Application drafts complete

Placeholder drafts for all four pages of the Waypoints application are above. Walk into the actual application form with these as starting clay, edit personally, route the finished draft through Jason and Robert, then submit. Application deadline: September 20, 2026. Selection decisions: September 28, 2026. Program begins: October 5, 2026.

Supporting links for the Waypoints reviewers

• /cell-demo.html · live cardiac_gen3 inference, signed manifests, public verification recipe
• /jason-plan.html · architectural plan (cell as opcode tree)
• /sister-cell.html · training plan, the TTRPG, and the trajectory
• /opcodes.html · the registered opcode table
• /registry/cardiac-registry.json · public cell-lineage registry

What Marjorie needs to provide before submission

• Marjorie's LinkedIn URL (question 2)
• Confirmation of the NN Inc operating address once the Delaware Certificate returns Mon Jul 6 via HBS (questions 5 through 10). Interim = registered agent address in Lewes, DE below.
• Elder Granger MG (Ret.) written confirmation that he is willing to be named in the application while the Board seat is finalized. Robert makes the ask.
• Referral answer for question 36 (how Marjorie learned of the Berg Innovation Exchange, in her own words).
• Executive summary exported as PDF (question 37 file upload).